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Purpose of the Study
Tenofovir (TDF) is a nucleotide reverse-transcriptase
inhibitor approved in 2001 for the treatment of HIV infec-
tion in adults. The benefits of TDF use in children has
been described in reducing metabolic toxicity. However,
the drug has been associated with renal toxicity and Fan-
coni syndrome in adults. We report two paediatric cases of
reversible severe Fanconi syndrome in children.
Clinical cases
Case No. 1
Anas is a 12 year-old Libyan boy with nosocomial-
acquired HIV infection in 1998. In February 2007 a first-
line ART has been started with TDF/FTC and LPV/r (CD4
255/mmc VL VL 1,398 cps/mL) with good response to
treatment (CD4 35% 461/mmc, viral load <400 cps/mL at
6 months). After 12 months he presented leg pain, proxi-
mal muscles weakness, paresthesia, and waddling gait.
The investigations done showed a hypophosphatemia
(1.2 mg/dL) and an increased level of alkaline phos-
phatase (1,879 UI/mL). Wrist X-ray was showing rickets
and osteopenia. TDF has been shifted to ABC and high
phosphate diet has been started. Six weeks later the child
showed dramatic clinical improvement, with reduction of
the pain and normalization of the gait. Phosphate levels
raised to normal values (3.6 mg/mL).
Case No. 2
Abdalla is a 10 year-old Libyan boy, diagnosed HIV
infected in December 2002 with severe immunodepres-
sion (CD4 1% 7/mmc and VL >500,000 cp/mL). A first-
line regimen with AZT-3TC-NFV was started with viro-
immunological improvement, and stopped in December
2005 because of virological failure due to low adherence.
In September 2006 (CD4 0%) he started ARV with ABC-
TDF-LPV/r with a good response (VL <400 cps/mL CD4%
8% at 6 months). After 18 months on ART he presented
generalized weakness, pain in lower limbs and abnormal
gait. The tests performed showed an hypophosphatemia
(1.1 mg/dL) and an increased level of alkaline phos-
phatase. The wrist X-ray was showing ricketic changes and
osteopenia. The suspension of TDF determined an
improvement of general conditions and normalizations
of laboratory results.
Conclusion
TDF-related tubular damage is well described in adults
and few cases have been described in children. Despite the
benefits of this drug, after initiation of TDF a vigilant
screening of renal function should be recommended espe-
cially in pre-pubertal children.
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